{
  "symbol": "BIIB",
  "year": 2022,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2044,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.242
  },
  "top_positive": [
    {
      "sent": "FAIR VALUE MEASUREMENTS The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of September 30, 2022 (In millions) Total Quoted\u00a0Prices in Active Markets (Level 1) Significant\u00a0Other Observable\u00a0Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 3,191.8 $ \u2014 $ 3,191.8 $ \u2014 Marketable debt securities: Corporate debt securities 1,219.1 \u2014 1,219.1 \u2014 Government securities 702.0 \u2014 702.0 \u2014 Mortgage and other asset backed securities 174.7 \u2014 174.7 \u2014 Marketable equity securities 896.0 896.0 \u2014 \u2014 Other current assets: Receivable from Samsung BioLogics (1) 790.8 \u2014 \u2014 790.8 Other assets: Derivative contracts 195.9 \u2014 195.9 \u2014 Plan assets for deferred compensation 32.2 \u2014 32.2 \u2014 Receivable from Samsung BioLogics (1) 402.8 \u2014 \u2014 402.8 Total $ 7,605.3 $ 896.0 $ 5,515.7 $ 1,193.6 Liabilities: Derivative contracts $ 22.8 $ \u2014 $ 22.8 $ \u2014 Contingent consideration obligations 195.4 \u2014 \u2014 195.4 Total $ 218.2 $ \u2014 $ 22.8 $ 195.4 (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9 % equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option.",
      "score": 0.9928
    },
    {
      "sent": "FAIR VALUE MEASUREMENTS The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of September 30, 2022 (In millions) Total Quoted\u00a0Prices in Active Markets (Level 1) Significant\u00a0Other Observable\u00a0Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 3,191.8 $ \u2014 $ 3,191.8 $ \u2014 Marketable debt securities: Corporate debt securities 1,219.1 \u2014 1,219.1 \u2014 Government securities 702.0 \u2014 702.0 \u2014 Mortgage and other asset backed securities 174.7 \u2014 174.7 \u2014 Marketable equity securities 896.0 896.0 \u2014 \u2014 Other current assets: Receivable from Samsung BioLogics (1) 790.8 \u2014 \u2014 790.8 Other assets: Derivative contracts 195.9 \u2014 195.9 \u2014 Plan assets for deferred compensation 32.2 \u2014 32.2 \u2014 Receivable from Samsung BioLogics (1) 402.8 \u2014 \u2014 402.8 Total $ 7,605.3 $ 896.0 $ 5,515.7 $ 1,193.6 Liabilities: Derivative contracts $ 22.8 $ \u2014 $ 22.8 $ \u2014 Contingent consideration obligations 195.4 \u2014 \u2014 195.4 Total $ 218.2 $ \u2014 $ 22.8 $ 195.4 (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9 % equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option.",
      "score": 0.9928
    },
    {
      "sent": "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
      "score": 0.9903
    }
  ],
  "top_negative": [
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    },
    {
      "sent": "If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.",
      "score": -0.9042
    }
  ],
  "forward_snippets": [
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "5 Table of Contents BIOGEN \nversions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "1,081.5 364.4 2,439.6 1,350.3 Comprehensive income (loss) attributable to noncontrolling interests, net of tax 0.2 ( 11.1 ) ( 84.4 ) 560.8 Comprehensive income (loss) $ 1,081.7 $ 353.3 $ 2,355.2 $ 1,911.1 See accompanying notes to these unaudited condensed consolidated fi\nr plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.",
    "We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology."
  ],
  "curated_text": "Symbol: BIIB. Year: 2022. Period: Q1. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FAIR VALUE MEASUREMENTS The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of September 30, 2022 (In millions) Total Quoted\u00a0Prices in Active Markets (Level 1) Significant\u00a0Other Observable\u00a0Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 3,191.8 $ \u2014 $ 3,191.8 $ \u2014 Marketable debt securities: Corporate debt securities 1,219.1 \u2014 1,219.1 \u2014 Government securities 702.0 \u2014 702.0 \u2014 Mortgage and other asset backed securities 174.7 \u2014 174.7 \u2014 Marketable equity securities 896.0 896.0 \u2014 \u2014 Other current assets: Receivable from Samsung BioLogics (1) 790.8 \u2014 \u2014 790.8 Other assets: Derivative contracts 195.9 \u2014 195.9 \u2014 Plan assets for deferred compensation 32.2 \u2014 32.2 \u2014 Receivable from Samsung BioLogics (1) 402.8 \u2014 \u2014 402.8 Total $ 7,605.3 $ 896.0 $ 5,515.7 $ 1,193.6 Liabilities: Derivative contracts $ 22.8 $ \u2014 $ 22.8 $ \u2014 Contingent consideration obligations 195.4 \u2014 \u2014 195.4 Total $ 218.2 $ \u2014 $ 22.8 $ 195.4 (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9 % equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. FAIR VALUE MEASUREMENTS The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value: Fair Value Measurements on a Recurring Basis As of September 30, 2022 (In millions) Total Quoted\u00a0Prices in Active Markets (Level 1) Significant\u00a0Other Observable\u00a0Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Cash equivalents $ 3,191.8 $ \u2014 $ 3,191.8 $ \u2014 Marketable debt securities: Corporate debt securities 1,219.1 \u2014 1,219.1 \u2014 Government securities 702.0 \u2014 702.0 \u2014 Mortgage and other asset backed securities 174.7 \u2014 174.7 \u2014 Marketable equity securities 896.0 896.0 \u2014 \u2014 Other current assets: Receivable from Samsung BioLogics (1) 790.8 \u2014 \u2014 790.8 Other assets: Derivative contracts 195.9 \u2014 195.9 \u2014 Plan assets for deferred compensation 32.2 \u2014 32.2 \u2014 Receivable from Samsung BioLogics (1) 402.8 \u2014 \u2014 402.8 Total $ 7,605.3 $ 896.0 $ 5,515.7 $ 1,193.6 Liabilities: Derivative contracts $ 22.8 $ \u2014 $ 22.8 $ \u2014 Contingent consideration obligations 195.4 \u2014 \u2014 195.4 Total $ 218.2 $ \u2014 $ 22.8 $ 195.4 (1) Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9 % equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Top negative sentences: If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Forward-looking snippets: Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. Reference is made in particular to forward-looking statements regarding: \u2022 the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments; \u2022 expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; \u2022 the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. 5 Table of Contents BIOGEN \nversions of our products or competing products; \u2022 patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity; \u2022 our plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. 1,081.5 364.4 2,439.6 1,350.3 Comprehensive income (loss) attributable to noncontrolling interests, net of tax 0.2 ( 11.1 ) ( 84.4 ) 560.8 Comprehensive income (loss) $ 1,081.7 $ 353.3 $ 2,355.2 $ 1,911.1 See accompanying notes to these unaudited condensed consolidated fi\nr plans and investments in our portfolio as well as implementation of our corporate strategy; \u2022 the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures; \u2022 the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators\u2019 pipeline products; \u2022 the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters; \u2022 our ability to finance our operations and business initiatives and obtain funding for such activities; \u2022 adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products; \u2022 the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees; \u2022 the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions; \u2022 the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products; \u2022 our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational; 3 Table of Contents \u2022 the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries; \u2022 lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and \u2022 the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology."
}